Logo image of APDN

APPLIED DNA SCIENCES INC (APDN) Stock Fundamental Analysis

NASDAQ:APDN - Nasdaq - US03815U5083 - Common Stock - Currency: USD

0.9  +0.09 (+11.11%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to APDN. APDN was compared to 55 industry peers in the Life Sciences Tools & Services industry. While APDN has a great health rating, there are worries on its profitability. While showing a medium growth rate, APDN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APDN has reported negative net income.
In the past year APDN has reported a negative cash flow from operations.
APDN had negative earnings in each of the past 5 years.
APDN had a negative operating cash flow in each of the past 5 years.
APDN Yearly Net Income VS EBIT VS OCF VS FCFAPDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

APDN has a Return On Assets of -147.70%. This is amonst the worse of the industry: APDN underperforms 96.36% of its industry peers.
With a Return On Equity value of -184.96%, APDN is not doing good in the industry: 87.27% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -147.7%
ROE -184.96%
ROIC N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
APDN Yearly ROA, ROE, ROICAPDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

APDN has a Gross Margin of 39.34%. This is in the lower half of the industry: APDN underperforms 60.00% of its industry peers.
APDN's Gross Margin has declined in the last couple of years.
APDN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
APDN Yearly Profit, Operating, Gross MarginsAPDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APDN has less shares outstanding
Compared to 5 years ago, APDN has more shares outstanding
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APDN Yearly Shares OutstandingAPDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
APDN Yearly Total Debt VS Total AssetsAPDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -29.53, we must say that APDN is in the distress zone and has some risk of bankruptcy.
APDN has a worse Altman-Z score (-29.53) than 96.36% of its industry peers.
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.53
ROIC/WACCN/A
WACC10.52%
APDN Yearly LT Debt VS Equity VS FCFAPDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

APDN has a Current Ratio of 4.72. This indicates that APDN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.72, APDN is doing good in the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 4.53 indicates that APDN has no problem at all paying its short term obligations.
APDN has a Quick ratio of 4.53. This is in the better half of the industry: APDN outperforms 74.55% of its industry peers.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.53
APDN Yearly Current Assets VS Current LiabilitesAPDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

APDN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -352.22%.
APDN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -58.46%.
The Revenue has been decreasing by -8.63% on average over the past years.
EPS 1Y (TTM)-352.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1455.56%
Revenue 1Y (TTM)-58.46%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%34.28%

3.2 Future

APDN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.37% yearly.
APDN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.04% yearly.
EPS Next Y-8.13%
EPS Next 2Y32.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APDN Yearly Revenue VS EstimatesAPDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
APDN Yearly EPS VS EstimatesAPDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -5K -10K -15K -20K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APDN. In the last year negative earnings were reported.
Also next year APDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APDN Price Earnings VS Forward Price EarningsAPDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APDN Per share dataAPDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40

4.3 Compensation for Growth

APDN's earnings are expected to grow with 32.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED DNA SCIENCES INC

NASDAQ:APDN (4/22/2025, 2:35:44 PM)

0.9

+0.09 (+11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-08 2025-05-08
Inst Owners26.59%
Inst Owner Change0%
Ins Owners6.97%
Ins Owner Change0%
Market Cap5.85M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short Ratio0.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.6%
Min EPS beat(2)-68.93%
Max EPS beat(2)7.73%
EPS beat(4)2
Avg EPS beat(4)38.69%
Min EPS beat(4)-68.93%
Max EPS beat(4)231.65%
EPS beat(8)6
Avg EPS beat(8)44.8%
EPS beat(12)9
Avg EPS beat(12)45.8%
EPS beat(16)9
Avg EPS beat(16)14.81%
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-11.33%
Max Revenue beat(2)13.1%
Revenue beat(4)1
Avg Revenue beat(4)-7.5%
Min Revenue beat(4)-27.61%
Max Revenue beat(4)13.1%
Revenue beat(8)4
Avg Revenue beat(8)-6.63%
Revenue beat(12)7
Avg Revenue beat(12)0.55%
Revenue beat(16)10
Avg Revenue beat(16)-0.5%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1968.97%
EPS NQ rev (3m)-971.43%
EPS NY rev (1m)-2196.65%
EPS NY rev (3m)-2196.65%
Revenue NQ rev (1m)13.73%
Revenue NQ rev (3m)7.56%
Revenue NY rev (1m)21.7%
Revenue NY rev (3m)1.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-48.84
EYN/A
EPS(NY)-5.61
Fwd EYN/A
FCF(TTM)-2.12
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0.57
BVpS1.96
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.7%
ROE -184.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.34%
FCFM N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score4
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.53
Altman-Z -29.53
F-Score4
WACC10.52%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-352.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1455.56%
EPS Next Y-8.13%
EPS Next 2Y32.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-58.46%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%34.28%
Revenue Next Year50.26%
Revenue Next 2Y45.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-71.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.41%
OCF growth 3YN/A
OCF growth 5YN/A